soluble programmed death-ligand 1

Overview

Soluble programmed death-ligand 1 (sPD-L1) is a circulating form of Programmed Death-Ligand 1 (PD-L1), an immune checkpoint ligand that normally participates in the regulation of T-cell activity through the PD-1/PD-L1 axis. Unlike membrane-bound PD-L1, which is expressed on cells within tissues and tumors, the soluble form is detectable in body fluids such as serum and is studied as a potential biomarker of immune activation, immune suppression, and disease severity.

Biologically, sPD-L1 is of interest because it may reflect or contribute to systemic immune regulation in cancer and infectious disease. In oncology, PD-L1 expression is often linked to immune evasion and resistance to therapy, including immunochemotherapy and (chemo)radiotherapy. In infectious disease, circulating sPD-L1 has been investigated as a marker associated with inflammatory state and clinical severity. Recent studies have also examined strategies aimed at suppressing PD-L1 more broadly, including transcriptional silencing and degradation-based approaches, which provide context for understanding the relevance of soluble PD-L1 in immune escape.

Recent Publications Focus

Below is a summary of the newest research publications targeting soluble programmed death-ligand 1 (sorted by publication date).

Recent studies have examined soluble programmed death-ligand 1 (sPD-L1) both as a biomarker and as part of broader PD-L1-directed therapeutic strategies. In scrub typhus, a multicenter retrospective study measured serum cytokine and chemokine profiles and found that sPD-L1 levels differed significantly across severity groups, trended lower during recovery, and showed a significant trend with increasing disease severity. At hospital admission, sPD-L1 demonstrated high discriminatory performance for identifying patients with organ dysfunction in two validation cohorts, supporting its potential use for early risk stratification.

Several publications focused on approaches to suppress PD-L1 function or expression in tumors. A programmable DNA hydrogel platform was designed to deliver polyvalent aptamer-based lysosome-targeting chimeras to promote extracellular PD-L1 degradation while also delivering siSMARCAL1 to silence transcriptional activation of PD-L1. This dual-mode “degrade-and-silence” strategy reduced PD-1/PD-L1-mediated immunosuppression, triggered immunogenic cell death, suppressed primary tumor growth, and prevented postoperative recurrence in murine melanoma models. In cervical cancer, the peptide UM-6 was reported to impair PD-L1 N-glycosylation, reduce its association with STT3A, and promote ER retention, polyubiquitination, and ERAD/proteasome-mediated degradation, thereby lowering functional PD-L1 at the cell surface and enhancing cytotoxic T-cell activity.

Other studies linked PD-L1 to resistance mechanisms and combination therapy responses. In cholangiocarcinoma, H3K4 methylation-driven CALB2 upregulation activated NF-κB, induced KRT7, and increased PD-L1 expression, which impaired T-cell activation and contributed to immune evasion and chemoradiotherapy resistance; CALB2 silencing reduced PD-L1 and sensitized tumors to gemcitabine plus radiotherapy. In cold tumors, GPX1 knockout restored sensitivity to cuproptosis inducers and improved the efficacy of PD-L1 blockade, placing GPX1 within a metabolic resistance axis relevant to immunotherapy response. A separate medicinal chemistry study identified a bispecific small molecule with activity against VEGFR2 and PD-L1, showing antiproliferative effects, apoptosis induction, and increased IFN-γ secretion in cancer cell models.

Clinical data in advanced Kras-mutant lung adenocarcinoma further assessed the relationship between PD-L1 expression and first-line immunochemotherapy outcomes. In this retrospective cohort, progression-free survival did not differ significantly across Kras subtypes or PD-L1 tumor proportion score groups, and PD-L1 expression was not predictive of progression-free survival within the major Kras subgroups. STK11 co-mutations were associated with shorter progression-free survival, indicating that factors beyond PD-L1 expression may influence treatment benefit in this setting.

Target PMIDs

• [PMID 41634944]
• [PMID 41880789]
• [PMID 41916036]
• [PMID 41936307]
• [PMID 42037422]
• [PMID 42258718]
• [PMID 42342561]
• [PMID 42392283]